Arcturus Therapeutics is trading at $11.40, down 5.2%, amid broader market pressure following hotter-than-expected September inflation data. - September headline CPI rose 3.7% year over year, above the 3.6% forecast; core CPI rose 2.6% year over year. - Reuters said the data heightened rate-hike concerns and pressured stocks; major U.S. indexes were lower. - No clear company-specific catalyst was identified for October 14, and available evidence does not establish a separate biotech-specific cause.